Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE) by B Ritchie
POSTER PRESENTATION Open Access
Fast 3: a phase III randomized double-blind,
placebo-controlled multicenter study of Icatibant
for subcutaneous injection in patients with acute
Attacks of Hereditary Angioedema (HAE)
B Ritchie
From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2009
Halifax, Canada. 22-25 October 2009
Background
Herditary Angioedema (HAE) is a rare disorder
(1:10,000 – 1:50,000) characterized by episodic, localized
edema of skin or mucosa of airway, genitourinary tract
or gastrointestinal tract. It is due to inherited deficiency
of the serpin known as C1 Inhibitor leading to unop-
posed kallikrein, producing excess bradykinin which
binds to G-protein coupled receptors known as B1 and
B2 receptors. Icatabant, a ten amino acid peptide analo-
gue of bradykinin is an effective blocker of the B2 recep-
tor and has been shown to provide rapid and complete
relief of symptoms compared to Tranexamic acid (Fast-
1) or placebo (Fast-2). Rapid relief of laryngeal edema
was confirmed in the open label arm. A new trial (Fast-
3) has begun. Primary Objective are to compare icati-
bant vs placebo on the time to symptom relief using a 3
symptom Visual Analog Scale (VAS) score during mod-
erate to very severe acute cutaneous and/or abdominal
attacks in patients with type I or type II hereditary
angioedema (HAE). Secondary Objectives are to com-
pare the global outcome following treatment with icati-
bant vs placebo using patient-reported (single symptom
and 8 symptom composite score) and physician-reported
outcome measures at 4 and 8 hours; to compare the
time to almost complete symptom relief following treat-
ment with icatibant vs placebo during moderate to very
severe acute cutaneous and/or abdominal attacks; to
assess safety and tolerability of icatibant vs placebo; and
to assess the efficacy and safety of open-label icatibant
treatment in patients experiencing laryngeal edema
attacks. 88 patients, aged 18 or older, with an attack of
at least moderate severity os skin, abdomen or larynx/
pharynx will be randomized to double-blind treatment
with either 30 mg of Icatabant SC or placebo.
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